Nonclinical models of pulmonary fibrosis
Experts in inflammatory disease models
Every August, IPST renews its commitment to help in the development of novel therapies against idiopathic pulmonary fibrosis and this year was no different as our team attended the IPF Summit in Boston.
Via presentations, publications, and sponsorships, IPST’s team of inflammation scientists shared the latest enhancements to the drug development toolbox available to innovators worldwide.
Contact us to discuss how we can work together to strengthen your drug development pipeline.
Email Charles at claurent@ipstherapeutique.com, or Daniel at dbarabino@ipstherapeutique.com to start the conversation.
Dedicated to scientific excellence since 1999, IPS Therapeutique (IPST) specializes in the preclinical evaluation of the efficacy and safety of new drugs using validated and highly predictive models.
Investigative-toxicology-V2
Reduce your costs of early drug development
De-risking pre-clinical drug candidates for scientists has been the focus of IPS Therapeutique (IPST) for 25 years; every in vivo model has been developed with this dual purpose in mind: confirm and define the conditions for efficacy, and identify early indicators of toxicity.
From proteomics to GLP-compliant safety pharmacology studies, IPST’s scientists understand the impact of attrition on drug discovery and use early detection of failure signals to lower the cost of pre-clinical development.
